Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -12.76% is 32% below its 5-year average of -9.68%, near the high end of its 5-year range (-330.47%–16.12%).
200.82% below its 12-month average of -4.24%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 16.12%.
EBITDA MARGIN
-12.76%
EBITDA MARGIN AVG TTM
-4.24%
EBITDA MARGIN AVG 3Y
-5.55%
EBITDA MARGIN AVG 5Y
-9.68%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-200.82%
CURRENT VS 3Y AVG
-130.08%
CURRENT VS 5Y AVG
-31.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
P3 Health Partners Inc.
Market Cap
$19.79M
EBITDA Margin
-12.76%
TTM Avg
-4.24%
3Y Avg
-5.55%
5Y Avg
-9.68%
Market Cap
$18.54M
EBITDA Margin
-779.07%
TTM Avg
-389.93%
3Y Avg
-389.93%
5Y Avg
-2320.55%
Market Cap
$19.76M
EBITDA Margin
-168.97%
TTM Avg
-358.59%
3Y Avg
-358.59%
5Y Avg
-358.59%
Market Cap
$18.05M
EBITDA Margin
-23.24%
TTM Avg
-24.75%
3Y Avg
-25.93%
5Y Avg
-17.56%
Market Cap
$20.99M
EBITDA Margin
-13586.02%
TTM Avg
-13586.02%
3Y Avg
-13586.02%
5Y Avg
-13586.02%
Market Cap
$17.17M
EBITDA Margin
-168.69%
TTM Avg
-262.41%
3Y Avg
-983.34%
5Y Avg
-3401.51%
Market Cap
$17.11M
EBITDA Margin
-521.61%
TTM Avg
-265.78%
3Y Avg
-984.51%
5Y Avg
-733.51%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| P3 Health Partners Inc. (PIII) | $19.79M | -12.76% | -4.24% | -5.55% | -9.68% |
| Actuate Therapeutics Inc (ACTU)vs › | $18.41M | N/A | N/A | N/A | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.54M | -779.07% | -389.93% | -389.93% | -2320.55% |
| NextCure, Inc. (NXTC)vs › | $19.76M | -168.97% | -358.59% | -358.59% | -358.59% |
| Cosmos Health Inc. (COSM)vs › | $18.05M | -23.24% | -24.75% | -25.93% | -17.56% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.99M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.99M | -13586.02% | -13586.02% | -13586.02% | -13586.02% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.17M | -168.69% | -262.41% | -983.34% | -3401.51% |
| Lipocine Inc. (LPCN)vs › | $17.11M | -521.61% | -265.78% | -984.51% | -733.51% |
| PAVmed Inc. (PAVM)vs › | $17.49M | -30564.79% | -16005.09% | -14551.39% | -13807.79% |
Gross Margin
-9.9%
EBITDA Margin
-12.8%
Operating Margin
-18.5%
Net Margin
-6.5%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 16.12% |
| 2026-03-31 | 7.59% |
| 2025-12-31 | -34.53% |
| 2025-09-30 | -6.72% |
| 2025-06-30 | -3.67% |
| 2025-03-31 | -4.56% |
| 2024-12-31 | -29.48% |
| 2024-09-30 | -23.56% |
| 2024-06-30 | -2.54% |
| 2024-03-31 | -5.74% |
| 2023-12-31 | -12.29% |
| 2023-09-30 | -4.20% |
| 2023-06-30 | 0.23% |
| 2023-03-31 | -9.03% |
| 2022-12-31 | -199.27% |
| 2022-09-30 | -15.39% |
| 2022-06-30 | -330.47% |
| 2022-03-31 | -11.12% |
| 2021-12-31 | -61.18% |
| 2021-09-30 | -17.71% |
| 2021-06-30 | -17.67% |
| 2021-03-31 | -8.36% |
| 2020-12-31 | -3.14% |
| 2020-09-30 | -10.30% |
| 2020-06-30 | -3.83% |
| 2020-03-31 | -5.18% |
